Cargando…
Assessment of Ondansetron-Associated Hypokalemia in Pediatric Oncology Patients
Objectives. Ondansetron is a 5-hydroxytryptamine (5-HT(3), serotonin) receptor antagonist used as antiemetic prophylaxis preceding chemotherapy administration. Hypokalemia is a rare complication of ondansetron, which may be underreported due to confounding emesis and chemotherapy-induced tubulopathy...
Autores principales: | Fiedrich, Elsa, Sabhaney, Vikram, Lui, Justin, Pinsk, Maury |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459247/ https://www.ncbi.nlm.nih.gov/pubmed/23050164 http://dx.doi.org/10.5402/2012/798239 |
Ejemplares similares
-
Severe Ondansetron-associated Hypokalemia in a Patient Diagnosed with Aspiration Pneumonia
por: Hakamifard, Atousa, et al.
Publicado: (2022) -
Prevalence and Management of Hypokalemia in Peritoneal Dialysis Patients in Qatar
por: Hamad, Abdullah, et al.
Publicado: (2019) -
Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine
por: Badar, Talha, et al.
Publicado: (2015) -
Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial
por: Freedman, Stephen B., et al.
Publicado: (2020) -
Ondansetron-droperidol combination vs. ondansetron or droperidol monotherapy in the prevention of postoperative nausea and vomiting
por: Matsota, Paraskevi, et al.
Publicado: (2015)